Boehringer’s $7.4B Stelis deal, Fresenius’ sweeping biosimilar pact and a bold $1B molecular glue push highlight Asia’s rising influence in global pharma strategy.
Boehringer’s $7.4B Stelis deal, Fresenius’ sweeping biosimilar pact and a bold $1B molecular glue push highlight Asia’s rising influence in global pharma strategy.